Literature DB >> 16920293

Effect of electroporation and pH on the iontophoretic transdermal delivery of human insulin.

Seiji Tokumoto1, Naruhito Higo, Kenji Sugibayashi.   

Abstract

The synergistic effect of electroporation (EP) and iontophoresis (IP) on the in vivo percutaneous absorption of human insulin was evaluated in rats. Passive diffusion and IP alone (0.4 mA/cm(2)) resulted in almost no skin permeation of insulin at pH 7, whereas EP treatment (150 or 300 V, 10 ms, and 10 pulses) resulted in a high plasma level of insulin and the combined use of EP and IP led to a further increase of the plasma level of insulin compared with that measured after EP alone. Interestingly, a much higher plasma level was observed when the pH of the insulin solution at 7 was increased to 10. One of the reasons was the different aggregation properties of insulin at pH 7 and pH 10. The nonassociation ratio of insulin was significantly higher at pH 10 than at pH 7. Insulin monomers and dimers were observed in addition to the normal form of insulin, hexamer, albeit in low percentages, at pH 10, whereas most of the insulin was in the hexamer form at pH 7. To confirm the influence of the aggregation properties of insulin, the commercially available human insulin analogue insulin lispro was then evaluated. Its skin permeation was found to be extremely high compared to that of conventional human insulin without increasing the solution pH. Marked decreases in blood glucose levels reflecting the increases in the plasma concentration of insulin were also observed after EP/IP treatment. The present study suggests that percutaneous absorption of insulin is synergistically enhanced by a combined use of EP and IP and that altering the aggregation properties of insulin is important to enhance the percutaneous absorption of insulin by IP and/or EP.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16920293     DOI: 10.1016/j.ijpharm.2006.07.002

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  7 in total

1.  Laser-engineered dissolving microneedle arrays for transdermal macromolecular drug delivery.

Authors:  Katarzyna Migalska; Desmond I J Morrow; Martin J Garland; Raj Thakur; A David Woolfson; Ryan F Donnelly
Journal:  Pharm Res       Date:  2011-03-25       Impact factor: 4.200

Review 2.  Advances in transdermal insulin delivery.

Authors:  Yuqi Zhang; Jicheng Yu; Anna R Kahkoska; Jinqiang Wang; John B Buse; Zhen Gu
Journal:  Adv Drug Deliv Rev       Date:  2018-12-08       Impact factor: 15.470

3.  Non-invasive and transdermal measurement of blood uric acid level in human by electroporation and reverse iontophoresis.

Authors:  Chih-Kuei Lee; Congo Tak-Shing Ching; Tai-Ping Sun; Chun-Lang Tsai; Wei Huang; Hsin-Hung Huang; Jen-Fu Kuo; Li-Hang Lai; Mei-Ya Chien; Hsin-Hui Tseng; Hui-Tzu Pan; Shiow-Yuan Huang; Hsiu-Li Shieh; Wei-Hao Liu; Chia-Ming Liu; Hsin-Wei Huang
Journal:  Int J Nanomedicine       Date:  2010-11-19

4.  A new approach for noninvasive transdermal determination of blood uric acid levels.

Authors:  Congo Tak-Shing Ching; Kok-Khun Yong; Yan-Dong Yao; Huan-Ting Shen; Shiu-Man Hsieh; Deng-Yun Jheng; Tai-Ping Sun; Hsiu-Li Shieh
Journal:  Int J Nanomedicine       Date:  2014-06-28

Review 5.  Delivery of Insulin via Skin Route for the Management of Diabetes Mellitus: Approaches for Breaching the Obstacles.

Authors:  Abdul Ahad; Mohammad Raish; Yousef A Bin Jardan; Abdullah M Al-Mohizea; Fahad I Al-Jenoobi
Journal:  Pharmaceutics       Date:  2021-01-14       Impact factor: 6.321

6.  Charge-switchable zwitterionic polycarboxybetaine particle as an intestinal permeation enhancer for efficient oral insulin delivery.

Authors:  Yan Li; Weihong Ji; Huan Peng; Ruichen Zhao; Tianlu Zhang; Zhiguo Lu; Jun Yang; Ruiyuan Liu; Xin Zhang
Journal:  Theranostics       Date:  2021-03-04       Impact factor: 11.556

Review 7.  Perspectives on Transdermal Electroporation.

Authors:  Kevin Ita
Journal:  Pharmaceutics       Date:  2016-03-17       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.